Table 2.
Detailed immunosuppressive regimen during the first year of transplantation
| Induction, n (%) | |
| IL-2 receptor antagonist | 137 (81.5) |
| Thymoglobulin | 31 (18.5) |
| Initial immunosuppressive therapy, n (%) | |
| Corticosteroids | 166 (100) |
| Tacrolimus | 98 (59) |
| Cyclosporine | 68 (41) |
| Mycophenolate mofetil | 165 (99.4) |
| First month, n (%) or mean ± SD | |
| Tacrolimus | 97 (58.4) |
| Trough level (ng/ml) | 8.8 ± 3 |
| Cyclosporine | 66 (39.8) |
| Trough level (ng/ml) | 222 ± 99 |
| Corticosteroids | 166 (100) |
| Dose (mg/d) | 21.3 ± 12.2 |
| Mycophenolate mofetil | 165 (99.4) |
| Dose (mg/d) | 2027 ± 480 |
| Azathioprine | 1 (0.6) |
| mTOR inhibitor | 4 (2.4) |
| Trough level (ng/ml) | 5 ± 2.6 |
| Belatacept | 3 (1.8) |
| Third month, n (%) or mean ± SD | |
| Tacrolimus | 78 (52.7) |
| Trough level | 8.1 ± 2.8 |
| Cyclosporine | 57 (39) |
| Trough level | 152 ± 76 |
| Corticosteroids | 135 (91.2) |
| Dose | 10 ± 7.8 |
| Mycophenolate mofetil | 131 (89.1) |
| Dose | 1597 ± 607 |
| Azathioprine | 1 (0.7) |
| mTOR inhibitor | 7 (4.8) |
| Trough level | 8.6 ± 3.3 |
| Belatacept | 5 (3.4) |
| Twelfth month, n (%) or mean ± SD | |
| Tacrolimus | 70 (53) |
| Trough level | 7 ± 3.4 |
| Cyclosporine | 50 (37.9) |
| Trough level | 121 ± 44 |
| Corticosteroids | 88 (65.7) |
| Dose | 6.1 ± 5.9 |
| Mycophenolate mofetil | 107 (82.3) |
| Dose | 1350 ± 599 |
| Azathioprine | 4 (3.1) |
| mTOR inhibitor | 8 (6) |
| Trough level | 8.4 ± 6.2 |
| Belatacept | 4 (3) |
IL, interleukin; mTOR, mammalian target of rapamycin.